AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|
26.9 C
New York
Sunday, July 5, 2026

Tag: investor

newssourceFORcompanyinformationcontent1releasesmarket

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

Llusern Scientific Announces Key Appointments to Strengthen its Executive Team

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide 
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

SASOL LIMITED: PRODUCTION AND SALES METRICS AND TRADING STATEMENT FOR THE YEAR ENDED 30 JUNE 2025

JOHANNESBURG, July 22, 2025 /PRNewswire/ -- Production and sales metrics for the year ended 30 June 2025 Sasol has published its production and sales performance metrics...

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CORZ, OLO, GMS on Behalf of Shareholders

NEW YORK, July 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of...

NBPE – Net Asset Value(s)

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Transaction in Own Shares

Transaction in Own Shares

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

Strong operational performance, but lower prices – refocused strategy for continued profitable growth

(Oslo, Norway, 22 July 2025) – Statkraft delivered strong operational performance in the second quarter of 2025, despite lower prices, especially in the northern price areas of Norway and Sweden. Net results were negatively impacted by impairments, mostly due to lower estimated future power prices in certain regions, and currency effects. Statkraft continues to refocus for profitable growth.

Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen er blevet accepteret til gennemgang af de canadiske lægemiddelmyndigheder

KØBENHAVN, Danmark, 22. juli 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de canadiske lægemiddelmyndigheder, Health Canada, har accepteret selskabets ansøgning om markedsføringstilladelse for den virus-lignende partikel (VLP)-baserede, enkelt-dosis chikungunyavaccinekandidat, CHIKV VLP, til forebyggelse af sygdom forårsaget af chikungunyavirus hos personer på 12 år og ældre. Dermed starter myndighedernes standardgennemgang, hvilket potentielt understøtter godkendelse af vaccinen i første halvår 2026.

Weekly progress on share repurchase program to cover share plans and reduce capital

Press Release

Greener Power Solutions appoints Jasper van den Driest as new CEO to lead next phase of growth

Van den Driest replaces outgoing CEO and founder Dieter Castelein as Greener targets further European expansionGreener has grown significantly since CVC DIF's investment in...

Greener Power Solutions appoints Jasper van den Driest as new CEO to lead next phase of growth

Van den Driest replaces outgoing CEO and founder Dieter Castelein as Greener targets further European expansionGreener has grown significantly since CVC DIF's investment in...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPTN, TURN, STRM on Behalf of Shareholders

NEW YORK, July 21, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers